CN1238041C - 一种治疗慢性疲劳综合症的口服液 - Google Patents
一种治疗慢性疲劳综合症的口服液 Download PDFInfo
- Publication number
- CN1238041C CN1238041C CN 01114111 CN01114111A CN1238041C CN 1238041 C CN1238041 C CN 1238041C CN 01114111 CN01114111 CN 01114111 CN 01114111 A CN01114111 A CN 01114111A CN 1238041 C CN1238041 C CN 1238041C
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- volatile oil
- liquor
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 claims abstract description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000341 volatile oil Substances 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims abstract description 12
- 241000489492 Arisaema Species 0.000 claims abstract description 9
- 210000000941 bile Anatomy 0.000 claims abstract description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 5
- 235000020374 simple syrup Nutrition 0.000 claims abstract description 5
- 235000014375 Curcuma Nutrition 0.000 claims abstract 2
- 244000111489 Gardenia augusta Species 0.000 claims abstract 2
- 241000208966 Polygala Species 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- 239000007788 liquid Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 11
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 11
- 241000208340 Araliaceae Species 0.000 claims description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 235000008434 ginseng Nutrition 0.000 claims description 8
- 239000009636 Huang Qi Substances 0.000 claims description 7
- 239000006185 dispersion Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 244000164439 Curcuma angustifolia Species 0.000 claims 1
- 241000545442 Radix Species 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 238000001914 filtration Methods 0.000 abstract 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 235000002848 Cyperus flabelliformis Nutrition 0.000 abstract 1
- 240000001505 Cyperus odoratus Species 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000008504 concentrate Nutrition 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 3
- FLDSMVTWEZKONL-AWEZNQCLSA-N 5,5-dimethyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,4,7,8-tetrahydrooxepino[4,5-c]pyrazole-3-carboxamide Chemical compound CC1(CC2=C(NN=C2C(=O)N[C@@H]2C(N(C3=C(OC2)C=CC=C3)C)=O)CCO1)C FLDSMVTWEZKONL-AWEZNQCLSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- 206010013789 Dry throat Diseases 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical group C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101710102916 Ichor Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
一种治疗慢性疲劳综合症的口服液，疗效显著。技术方案：将郁金、柴胡、砂仁、香附、川芎提取挥发油，提取挥发油后的药液滤过，滤液、药渣备用；将红参、黄芪、远志、栀子、胆南星加入前述药渣煎煮后的滤液与提油后的药液合并，浓缩至清膏，加乙醇，滤过，滤液回收至无醇味，残液的离心液加入吐温80溶解的挥发油，加单糖浆混合均匀加水而成。
Description
技术领域：本发明涉及一种治疗慢性疲劳综合症的口服液。
背景技术：在发达国家中，患慢性疲劳综合症的患病率约为千分之三。据统计，美国现有200～600万人患病。旧本称此病为过劳死，日本近5年内有150位市长因长时间的过度劳累，患此病征而致死亡。我国目前尚无统计资料，但据临床观察并不鲜见，而以脑力劳动者为多。随着我国经济的发展，现代快节奏和竟争，来自生活、工作、学习等各方面的压力越来越大，疲劳综合症的发病率呈上升趋势。1988年由美国疾病控制中心正式命名。1999年10月，新版《实用内科学》已收载了慢性疲劳综合症。目前该病仅是临床诊断，其疲劳不能通过休息解决，且末发现引起疲劳的内科或精神科疾病，故尚不能作出实验诊断，也未提出有效的治疗方法。因此尚无治疗此病的中西药物。由于本病病程较长，一般在半年以上，甚则数年，严重影响患者的学习与工作效率。因此，研制治疗慢性疲劳综合症疾病的有效药物，是目前医药学界关注的研究课题之一，具有重大意义，又具有良好的前景。目前，治疗慢性疲劳综合症的药物尚属空白。
本发明的内容：克服现有技术存在的不足，提供一种能够有效治疗慢性疲劳综合症的药品。一种治疗慢性疲劳综合症的口服液，由以下重量份的原料药物制成，红参2.5-2.9、份、柴胡4.0-4.4份、黄芪5.1-5.5份、郁金2.1-2.5份、香附2.1-2.5份、远志2.5-2.9份、川芎2.5-2.9份、桅子2.1-2.5份、胆南星1.5-1.9份、砂仁0.8-1.2份，将郁金、柴胡、砂仁、香附、川芎提取挥发油，提取挥发油后的药液滤过，滤液及药渣备用，其余红参、黄芪、远志、桅子、胆南星，酌予碎断，加入上述药渣，加水煎煮三次，每次2小时，合并煎液，滤过，与提油后的药液合并，加热浓缩成相对密度1.1-1.15(80℃热测)的清膏，加乙醇使含醇量达70％，静置24小时，滤过，滤液回收乙醇至无醇味，残液加2倍量水使分散，离心去沉淀物，离心液加入用吐温80溶解的挥发油，加入单糖浆混合均匀后加水，分装灭菌而成。
本发明的有益效果：本发明的药品以黑龙江省中医药大学附属一院、黑龙江省五院、黑龙江省中西医结合研究所附属医院三家省级医院进行临床试验。试验目的：考察其疗效在同类药品中的领先地位及安全性，故设立对照组，对照药品选用疗效好的刺五加脑灵液，共观察了432例，其中本发明的药品观察325例，对照组观察107例。试验结果表明：本发明的药品服用安全可靠，无任何毒副作用，有显著的治疗因工作和学习过度劳累、作息无规律而致的慢性疲劳综合症。症见倦怠乏力，头昏头胀，思维不集中，胁肋胀痛，口苦咽干或咽痛，不思饮食，大便不调，急躁易怒，紧张性头痛、肌肉痛、失眠健忘或嗜睡等。(详见附表1～2)
表1观察两组服药前后征状变化比较
| 观察组 | 征状 | 主证等级 | 主证等级 | U P | ||||||||||
| ++++ | +++ | ++ | + | - | ++++ | +++ | ++ | + | - | |||||
| 神疲懒言体倦乏力胃纳减少脘腹隐痛食后腹胀大便溏而不爽胸肋、少腹胀痛嗳气吞酸烦躁易怒失眠多梦或睡眠过多口苦、咽干或咽痛头昏头胀思维不集中、健忘头痛、肌肉痛、关节痛心慌气短或汗出 | 治前治后治前治后治前治后治前治后治前治后治前治后治前治后治前治后治前治后治前治后治前治后治前治后 | 32715343140066280052838861881432200 | 16045901610362452168362617113499237822393387318127 | 8484136537278866683599568108861337810770116661821259764 | 4987521045879871088615187995210362909011728813876173169 | 01023214949921071201251117141079011240114012601044375 | 对照组 | 115521490021130016613623271710200 | 533228153521142231881381231202820322218642 | 262849362428291827313117364844363529382861543226 | 172617321930284229302929172819422946103318315758 | 01882215193645715395101308139070141421 | 4.12 ＜0.055.75 ＜0.051.96 ＜0.052.11 ＜0.052.36 ＜0.051.97 ＜0.052.79 ＜0.052.51 ＜0.053.37 ＜0.053.42 ＜0.053.18 ＜0.051.00 ＞0.05 | |
经用Ridit检验进行统计学处理，本发明对慢性疲劳综合症治疗效果显著，与观察组有显著差异。
表2观察两组服药后疗效对比表
| 组别 | n | 痊愈％ | 显效％ | 有效％ | 无效％ | 愈显％ | 总有效％ |
| 观察组对照组 | 325107 | 88(27.1)28(24.3) | 115(35.3)30(28.0) | 98(30.2)32(30.0) | 24(7.4)17(5.9) | 62.554.21 | 92.681.1 |
经Ridit分析，u＝-2.05，P＜0.05。
毒性试验：经动物急性毒性试验及长期毒性试验，该药无任何毒副作用。(详见附表3～6)
表3本发明对大白鼠体重增长结果(g、
X±SD)
| 组别 | 动物数(只) | 给药前体重 | 给药后体重 | 增加重量 ％ |
| 空白对照低剂量组中剂量组高剂量组 | 20202020 | 94.8±10.1102.2±9.997.1±8.293.8±9.1 | 235.37±8.1231.7±11.6230.2±10.8238.2±13.1 | 136.7 141.0120.1 125.6132.6 140.5138.6 143.9 |
表4本发明对大白鼠血液学指标检测结果(
X±SD)
| 组别 | 动物数(只) | RBC(×1012/L) | Hb(g/L) | WBC(×109/L) | WBC分类(％) | |
| LY | GR | |||||
| 空白对照低剂量组中剂量组高剂量组 | 20202020 | 4.10±0.324.86±0.424.71±0.564.80±0.31 | 128±9.2130±10.5127±8.2131±11.7 | 7.24±1.618.01±1.857.65±2.137.95±1.74 | 68.7±5.471.4±4.669.2±3.272.8±5.8 | 25.1±3.420.6±5.824.1±4.321.7±5.6 |
表5本发明对大白鼠血液生化学指标检测结果(
X±SD)
| 组别 | 动物数(只) | BUN(mmol/L) | Grea(μmol/L) | SGPT(nmol/L) | SGOT(nmol/L) |
| 空白对照低剂量组中剂量组 | 202020 | 5.7±0.96.1±1.05.5±1.5 | 80.1±10.576.8±12.478.2±8.8 | 71.5±11.664.2±11.469.3±8.9 | 113.8±30.4111.7±17.9108.9±25.4 |
| 高剂量组 | 20 | 6.1±1.2 | 77.9±12.1 | 70.0±12.4 | 110.8±19.9 |
表6本发明对大白鼠主要脏器系数计算结果(％
X±SD)
| 组别 | 动物数(只) | 心脏 | 肝脏 | 脾脏 | 肺脏 | 肾脏 |
| 空白对照低剂量组中剂量组高剂量组 | 20202020 | 0.50±0.030.52±0.040.49±0.030.51±0.03 | 3.61±0.323.40±0.273.54±0.253.61±0.32 | 0.31±0.010.28±0.030.25±0.040.27±0.03 | 0.90±0.130.82±0.140.86±0.170.90±0.15 | 0.74±0.130.65±0.110.72±0.150.68±0.11 |
药效学试验：本发明以低、中、高三个剂量组进行药效学实验，实验结果显示该药具有镇痛、镇静、改善学习、记忆，抗缺氧、抗疲劳，以及提高免疫机能的作用。(详见附表7～13)
表7本发明对大鼠的镇痛作用(热板法
X±SD)
| 组别 | 动物数(只) | 剂量g(ml)/kg | 药后不同时间(分)30 | 痛阈差值60 |
| 低剂量中剂量高剂量阳对药对照组 | 2020202020 | 6.913.827.6(2.6)等量 | 2.05±2.354.45±5.625.35±4.55*48.5±2.691.15±2.75 | 2.85±3.033.85±3.993.35±5.0948.5±2.69**1.45±2.95 |
与对照组比较*P＜0.05 **P＜0.01。
表8本发明对大鼠的镇痛作用(扭体法
X±SD)
| 组别 | 动物数(只) | 剂量g(ml)/kg | 20分内扭体次数 |
| 低剂量中剂量高剂量阳对药对照药 | 2020202020 | 6.913.827.6(2.6)等量 | 19.7±6.87**13.2±11.6**12.2±4.62**0.1±0.3***48.4±17.5 |
与空白对照组比较**P＜0.01，***P＜0.001。
表9本发明对大鼠的镇静作用(
X±SD)
| 组别 | 动物数(只) | 剂量g(ml)/kg | 活动次数(次) |
| 低剂量中剂量高剂量阳对药对照组 | 2020202020 | 6.913.827.62.6- | 227.5±52.3**187.6±49.7**160.7±51.7**199.3±52.1**358.2±60.8 |
**与对照组比较p＜0.01。
表10本发明对东莨菪碱所致大鼠记忆再障碍的改善作用(
X±SD)
| 组别 | 剂量(/kg po) | 动物数(只) | 潜伏期(秒) | 5内错误次数(次) |
| 对照(自来水)造型 东莨菪碱阳性药+造型高剂量组+造型中剂量组+造型低剂量组+造型 | 20ml2mg2.6g27.6g13.8g6.9g | 202020202020 | 1.88±1.3622.12±16.68ΔΔ17.65±17.9418.06±16.7116.41±15.3416.82±19.14 | 1.29±4.339.12+5.19Δ4.24±4.76*4.82±6.644.76±5.83*5.29±6.423 |
与对照组比较ΔP＜0.05，ΔΔP＜0.01。
表11本发明对大鼠游泳时间的影响(
X±SD)
| 组别 | 动物数(只) | 剂量g(ml)/kg | 游泳时间(min) |
| 高剂量中剂量低剂量阳对药空白组 | 2020202020 | 27.613.86.9(2.6) | 28.89±2.17**21.65±1.98**23.13±2.78**20.12±3.32*15.77±3.74 |
各用药组与空白组对照组比较*P＜0.05，**P＜0.01。
表12本发明对大鼠耐常压缺氧的作用(
X±SD)
| 组别 | 动物数(只) | 剂量g(ml)/kg | 存活时间(min) |
| 高剂量中剂量低剂量阳对药空白组 | 2020202020 | 27.613.86.9(2.6) | 29.76±2.90**22.54±1.99**18.55±3.35**24.13±2.78**12.97±1.87 |
各用药组与空白组比较*P＜0.05，**P＜0.01。
表13本发明对脾虚大鼠免疫功能的影响(
X±SD)
| 组别 | 动物数(只) | 剂量(g/kg) | 血清半数溶血指数(HC50) | 血清凝集指数(K) | 脾脏系数(mg/g) |
| 高剂量中剂量低剂量阳对药空白组模型组 | 202020202020 | 2.7613.86.9(2.6)// | 897±290885±234*852±215813±228997±287*685±199 | 189±22.3*176±19.8181±20.0*190±26.6*213±28.9**185±25.7 | 4.56±0.894.21±0.734.77±0.944.11±0.675.81±1.06**3.87±1.02 |
各用药组与空白组比较*p＜0.05，**p＜0.01。
下面详述本发明的一个最佳实施例，取红参2.9g、柴胡4.0g、黄芪5.1g、郁金2.1g、香附2.1g、远志2.5g、川芎2.1g、栀子2.1g、胆南星1.5g，砂仁0.8g，将郁金、柴胡、砂仁、香附、川芎提取挥发油，提取挥发油后的药液滤过，滤液及药渣备用，其余红参、黄芪、远志、栀子、胆南星，酌予碎断，加入上述药渣，加水煎煮三次，每次2小时，合并煎液，滤过，与提油后的药液合并，加热浓缩到相对密度1.10～1.15(80℃热测)的清膏，加乙醇使含醇量达70％，静置24小时，滤过，滤液回收乙醇至无醇味，残液加2倍量水使分散，离心去沉淀物，离心液加入用适量吐温80溶解的挥发油，加入单糖浆混合均匀后加水适量，分装灭菌而成。口服每次2-3支，每日3次，每支10ml。
本发明的第二个最佳实施例，取红参2.5g、柴胡4.4g、黄芪5.5g、郁金2.5g、香附2.5g、远志2.9g、川芎2.5g、栀子2.5g、胆南星1.9g，砂仁1.2g，将郁金、柴胡、砂仁、香附、川芎提取挥发油，提取挥发油后的药液滤过，滤液及药渣备用，其余红参、黄芪、远志、栀子、胆南星，酌予碎断，加入上述药渣，加水煎煮三次，每次2小时，合并煎液，滤过，与提油后的药液合并，加热浓缩到相对密度1.10～1.15(80℃热测)的清膏，加乙醇使含醇量达70％，静置24小时，滤过，滤液回收乙醇至无醇味，残液加2倍量水使分散，离心去沉淀物，离心液加入用适量吐温80溶解的挥发油，加入单糖浆混合均匀后加水适量，分装灭菌而成。口服每次2-3支，每日3次，每支10ml。
Claims (2)
1、一种治疗慢性疲劳综合症的口服液，其特征在于：由以下重量份的原料药物制成：红参2.5～2.9份、柴胡4.0～4.4份、黄芪5.1～5.5份、郁金2.1～2.5份、香附2.1～2.5份、远志2.5～2.9份、川芎2.1～2.5份、栀子2.1～2.5份、胆南星1.5～1.9份，砂仁0.8～1.2份。
2、如权利要求1所述的口服液生产工艺，其特征在于：按上述原料药物重量配比，将郁金、柴胡、砂仁、香附、川芎提取挥发油，提取挥发油后的药液滤过，滤液及药渣备用，其余红参、黄芪、远志、栀子、胆南星，酌予碎断，加入上述药渣，加水煎煮三次，每次2小时，合并煎液，滤过，与提油后的药液合并，加热浓缩到相对密度1.10～1.15的清膏、80℃热测，加乙醇使含醇量达70％，静置24小时，滤过，滤液回收乙醇至无醇味，残液加2倍量水使分散，离心去沉淀物，离心液加入用吐温80溶解的挥发油，加入单糖浆混合均匀后加水，分装灭菌而成。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01114111 CN1238041C (zh) | 2001-06-18 | 2001-06-18 | 一种治疗慢性疲劳综合症的口服液 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01114111 CN1238041C (zh) | 2001-06-18 | 2001-06-18 | 一种治疗慢性疲劳综合症的口服液 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1391919A CN1391919A (zh) | 2003-01-22 |
| CN1238041C true CN1238041C (zh) | 2006-01-25 |
Family
ID=4660786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01114111 Expired - Lifetime CN1238041C (zh) | 2001-06-18 | 2001-06-18 | 一种治疗慢性疲劳综合症的口服液 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1238041C (zh) |
-
2001
- 2001-06-18 CN CN 01114111 patent/CN1238041C/zh not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1391919A (zh) | 2003-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1121811A (zh) | 一组治疗神经症的药物配方及其制法 | |
| CN1895547A (zh) | 一种治疗糖尿病的药物及制备方法 | |
| CN109908194A (zh) | 一种用于治疗急慢性咽炎的药物及其制备方法 | |
| CN1927324A (zh) | 用于治疗妇女月经不调中药制剂的制备方法 | |
| CN1031318C (zh) | 藿香正气液体口服制剂的制备方法 | |
| CN1238041C (zh) | 一种治疗慢性疲劳综合症的口服液 | |
| CN1692938A (zh) | 一种用于明目的中药复方制剂及其制备方法 | |
| CN103520684B (zh) | 一种降血糖的中药复合物 | |
| CN103536879B (zh) | 一种治疗糖尿病的药物组合物以及制备方法 | |
| CN105727089A (zh) | 含艾叶的药物组合物用于制备治疗肠易激综合症药物中的用途 | |
| CN1232287C (zh) | 一种治疗干燥综合症的中药制剂及其制备方法 | |
| CN100464773C (zh) | 一种益气复脉、活血化瘀的益心舒注射制剂及其制备方法 | |
| CN1081042C (zh) | 中药戒毒药物组合物及其制备工艺 | |
| CN104587389A (zh) | 一种治疗颈肩腰腿痛的中药组合物 | |
| CN1686194A (zh) | 一种治疗偏头痛的药及其制备方法 | |
| CN105998752B (zh) | 一种防治血管性痴呆的中药组合物 | |
| CN116211924B (zh) | 一种中药组合物在制备治疗神经炎药物中的用途 | |
| CN1113804A (zh) | 一种抗贫血冲剂及其制备方法 | |
| CN108079113A (zh) | 一种治疗产后血虚的药物组合物及其制备方法 | |
| CN1283482A (zh) | 一种治心血管病的药物组合物及其制备方法 | |
| CN102727749B (zh) | 一种治疗再生障碍性贫血的药物 | |
| CN117599145B (zh) | 一种治疗冠心病的组合物 | |
| CN102205104A (zh) | 一种治疗小儿咳嗽疾病的复方口服液及其制备方法 | |
| CN108653526B (zh) | 中医治疗重症肌无力的药方 | |
| CN1058167C (zh) | 附片口服液及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Liu Yuhui Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice |
Addressee: Liu Yuhui Document name: Notification to Pay the Fees |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20030122 Assignee: Heilongjiang days Ge Pharmaceutical Co., Ltd. Assignor: Liu Yuhui Contract record no.: 2014230000138 Denomination of invention: Lifuji oral liquor Granted publication date: 20060125 License type: Exclusive License Record date: 20140421 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EM01 | Change of recordation of patent licensing contract |
Change date: 20141203 Contract record no.: 2014230000138 Assignee after: Harbin traditional Chinese medicine four factory Co., Ltd. Assignee before: Heilongjiang days Ge Pharmaceutical Co., Ltd. |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Liu Yuhui Document name: Notification that Application Deemed not to be Proposed |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Xiuling Inventor before: Liu Yuhui |
|
| COR | Change of bibliographic data | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170223 Address after: Nanjing Road East three street in Heilongjiang city of Harbin Province Traditional Chinese medicine 150025 Limin development zone four factory Patentee after: Zhang Xiuling Address before: 150001 Wenchang street, Nangang District, Heilongjiang, China, No. 1, No. Patentee before: Liu Yuhui |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Liu Yuhui Document name: Notification of Passing Examination on Formalities |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180808 Address after: 150025 the four Chinese herbal medicine factory of Nanjing Road East three street, liming Development Zone, Harbin, Heilongjiang Patentee after: Harbin traditional Chinese medicine four factory Co., Ltd. Address before: 150025 the four Chinese herbal medicine factory of Nanjing Road East three street, liming Development Zone, Harbin, Heilongjiang Patentee before: Zhang Xiuling |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060125 |
|
| CX01 | Expiry of patent term |